Strong INTERPHEX 2013 an Indicator of Industry Regrowth - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strong INTERPHEX 2013 an Indicator of Industry Regrowth


More than 12,000 industry professionals, including 8,100 show attendees, participated in INTERPHEX 2013, a 20% increase over the 2012 show, the show organizers report. The event, held April 23-25 at the Javits Center in New York, gave visitors the opportunity to connect with vendors and suppliers, while receiving the latest information on tools, methodologies and regulatory knowledge.

Congressman Bill Cassidy M.D.’s keynote presentation, “Policy Recommendations for Improving Patient Access to Drugs in Shortage”, offered potential improvements to the current reimbursement system to avoid future drug shortages. Another keynote session entitled “Reorganizing for the Future: Succeeding in the New Pharmaceutical Industry” featured Rajesh Nair, M.D., President of Indegene. Jim Miller, President, PharmSource Information Services, Inc., presented Recalibrating The Pharmaceutical Services Opportunity, in a third keynote, sponsored by Pharmaceutical Technology magazine.


PharmTech Publisher Mike Tracey (l) and Bob Stewart, Industry Vice President, INTERPHEX Events, meet on the floor of INTERPHEX 2013.
Buyers had the opportunity to connect and network with new suppliers displaying the latest technologies. Exhibit Hall Technology Floor Tours  offered critical insights followed by a walking tour to select vendors to showcase the latest technology and equipment on the Show Floor.

Russ Somma, PhD, INTERPHEX Advisory Board Member and Conference Speaker, stated, “Our event formula entailed attendees first be given real-time knowledge within the conference sessions that they could take to the Exhibit Hall to source specific organizational needs. We were confident that once the event ended our attendees could return to their firms and implement quickly what was gleaned at INTERPHEX. Learning, networking and implementation: a simple formula that can yield unprecedented success.” “We’re thrilled with the signs of industry optimism that were evident at this year’s INTERPHEX. We saw an increased demand for product sourcing with a higher number of open industry projects fueling a surge in attendance, “ noted Bob Stewart, Industry Vice President, INTERPHEX Events. “We at INTERPHEX will continue to bring insightful and critical information to our future attendees, and we look forward to seeing all next year, March 18-20, 2014 at the Javits Center in New York City.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here